Dhaka, April 23 -- Recent enforcement actions by US authorities are drawing renewed attention to the risks posed by online sales of counterfeit pharmaceuticals, particularly those involving synthetic opioids such as fentanyl, according to a new analysis of publicly available government data and court filings.

In February 2026, the US Drug Enforcement Administration (DEA), working with international partners, announced an enforcement initiative targeting online networks allegedly involved in the sale of counterfeit prescription medications. According to official statements, the operation resulted in the seizure of more than 200 internet domains linked to suspected illicit pharmacy activity.

Public data and government reports indicate tha...